Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00585273 · ClinicalTrials.gov registry record

Antipsychotics and Blood Vessel Function

A clinical trial of Schizophrenia and Bipolar Disorder, sponsored by Jess G. Fiedorowicz.

Completed
Registry status
44
Enrollment target
1
Study location

NCT00585273: Completed study of Schizophrenia and Bipolar Disorder, sponsored by Jess G. Fiedorowicz.

NCT00585273 is a study of Schizophrenia and Bipolar Disorder that has completed, run by Jess G. Fiedorowicz. The registered enrollment target is 44 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00585273, a study of Schizophrenia and Bipolar Disorder, has completed, sponsored by Jess G. Fiedorowicz.

COMPLETED
Registry status
44 participants
Enrollment target
1
Study location

Study Summary

Over the last decade, second generation antipsychotics have been increasingly utilized. Since their introduction, however, atypical antipsychotics have been increasingly associated with significant metabolic complications including hyperlipidemia, insulin resistance/diabetes mellitus, and obesity. These metabolic complications increase the risk for cardiovascular disease in populations with an already elevated risk. The initial goal of the proposed study is to identify early signs of endothelial dysfunction and vascular disease in those treated with atypical antipsychotics. The identification of early signs of vascular disease may further link metabolic complications with any cardiovascular risk. Demonstration of changes in vascular function associated with atypical antipsychotics represents an important identifiable intermediate of more long-term cardiovascular risk. The second goal of the proposed study is to identify genetic factors that may be associated with the development of cardiovascular disease, which can later serve as a guide to predict risk. Accurate prediction of risk may facilitate the future development of an empirical, risk-based, individualized selection process for antipsychotic medications. Aim 1: To quantify the role of antipsychotic-induced metabolic complications on the development of vascular disease using measures of endothelial function. Hypothesis 1: Atypical antipsychotics will lead to greater impairments in endothelial function, evidenced by decreased flow-mediated dilation from baseline measures and compared with changes over time in controls. Medication-induced metabolic complications will be temporally associated with these impairments in endothelial function. Aim 2: To investigate the role of candidate pharmacogenetic polymorphisms with cardiovascular and metabolic complications of atypical antipsychotics. Hypothesis 2: Profiles of polymorphisms at receptors targeted by atypical antipsychotics will be associated with impaired c

Primary Outcome

% dilation of the brachial artery in response to 5 minutes of ischemia

Study Locations (1)

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2007-09
Est. Completion 2014-12
Jess G. Fiedorowicz

1 total trials

What the finished NCT00585273 record still lists

NCT00585273 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (80% lower).

The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.

NCT00585273 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT00585273 about?

NCT00585273 is a clinical study titled "Antipsychotics and Blood Vessel Function". Over the last decade, second generation antipsychotics have been increasingly utilized. Since their introduction, however, atypical antipsychotics have been increasingly associated with significant metabolic complications including hyperlipidemia, insulin resistance/diabetes mellitus, and obesity. T...

What is the current status of trial NCT00585273?

This trial is currently completed. The enrollment target is 44 participants. The study started on 2007-09. Estimated completion is 2014-12.

What conditions does trial NCT00585273 study?

This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder.

Who is sponsoring clinical trial NCT00585273?

This trial is sponsored by Jess G. Fiedorowicz, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00585273 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00585273's enrollment target sits among peer trials

44 230th of 315 higher than 84 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00585273, the US trial registry maintained by the National Library of Medicine. NCT00585273 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.